DJIA 17,976.31 263.65 1.49%
NASDAQ 4,947.44 56.22 1.15%
S&P 500 2,086.24 25.22 1.22%
market minute promo

Novo Nordisk (NYSE: NVO)



company name or ticker
Company Photos
(Click to zoom)

Novo-Nordisk's Oral GLP-1 Diabetes Treatment: An Update

To Reinvest or Not Reinvest: That is the Question

3 Drugs Stocks Pushing Industry Growth

Week In Review: Cellular Biomedicine In-Licenses Cancer Immunotherapy From China

Baxter Announces Positive Data for BAX 855; Competition Rife - Analyst Blog

Don't Worry About Orexigen's Obesity Drug EU Approval

Despite what looks initially like bad news for the oral obesity drug, a positive European Commission decision is still likely.

Guru Stocks at 52-Week Lows: BABA, NVO, PCLN, ING, EMR

Forget About Ebola Stocks and Invest in This Instead

Instead of Ebola drugmakers, investors may be better served focusing on these healthcare trends.

Forget Pfizer! This Big Pharmaceutical Stock is Better

Novo Nordisk's growth opportunity could make it a better buy than Pfizer Inc.

What MannKind Investors Can Learn From The Sanofi Conference Call

See More Articles...